Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.58 |
| ▸ | WNT3A | P56704 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908275 | 0.89 | ALDH1A1 (0.56) | ENPP2CTNNB1WNT3ASLC6A2SLC6A3 | |
| SCHEMBL27294389 | 0.87 | NFATC1 (0.48) | ENPP2CTNNB1WNT3ASLC6A2SLC6A3 | |
| SCHEMBL6002245 | 0.82 | KMT2A (0.70) | SLC6A2SLC6A3KMT2ATDP1LMNA | |
| SCHEMBL1222893 | 0.80 | MAOA (0.67) | CTNNB1WNT3AKMT2AALDH1A1MAPT | |
| SCHEMBL31094660 | 0.80 | MAOA (0.67) | CTNNB1WNT3AKMT2AALDH1A1MAPT | |
| SCHEMBL20782366 | 0.80 | MAPK14 (0.71) | ENPP2CTNNB1WNT3ASLC6A2SLC6A3 | |
| SCHEMBL6195034 | 0.80 | ENPP2 (0.43) | ENPP2CTNNB1WNT3ASLC6A2SLC6A3 | |
| SCHEMBL2706461 | 0.79 | KMT2A (0.66) | SLC6A2SLC6A3KMT2ATDP1LMNA | |
| SCHEMBL23397120 | 0.78 | TDP1 (0.60) | SLC6A2SLC6A3KMT2ATDP1LMNA | |
| Hydrochloric Acid SCHEMBL28263903 | 0.78 | MAOA (0.65) | CTNNB1WNT3AKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-1595866-B1 | Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome | SANWA KAGAKU KENKYUSHO CO (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| EP-0489547-B1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1998-07-29 | — | — | EP | disclosed |
| EP-0432984-B1 | Carbamoyl derivatives | ZENECA LTD (GB) | 1998-03-04 | — | — | EP | disclosed |
| US-5334765-A | Intermediate for leukotriene antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-08-02 | — | — | US | disclosed |
| US-5286740-A | Leukotrine antagonists; antiinflammatory agnets, antiallergens, treating asthma | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-15 | — | — | US | disclosed |
| US-5280125-A | Chemical process for the preparation of 3-alkylated indole | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0489547-A1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0432984-A2 | Carbamoyl derivatives | ZENECA LIMITED (GB) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | ENPP2 3872/4885CTNNB1 1337/4885WNT3A 3843/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | ENPP2 3201/4885CTNNB1 2027/4885WNT3A 3114/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | ENPP2 3201/4885CTNNB1 2027/4885WNT3A 3114/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | ENPP2 3201/4885CTNNB1 2027/4885WNT3A 3114/4885 |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | ENPP2 2894/4885CTNNB1 2887/4885WNT3A 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.